NCT03043599 - Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

October 26, 2018

Study Completion Date

November 16, 2023

Conditions

Small Cell Lung CancerExtensive-stage Small Cell Lung Cancer

Interventions

RADIATION

Thoracic Radiation Therapy

All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).

DRUG

Ipilimumab

Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.

DRUG

Nivolumab

Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa